RGNX: Late-stage gene therapy programs show strong efficacy, with financial runway into Q4 2027
The company is advancing late-stage gene therapy programs in DMD and retina, with RGX-202 showing strong efficacy and safety, and pivotal wet AMD trials with AbbVie targeting significant reduction in injection burden. Financial runway extends into late 2027, with potential for further extension fro…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.